31 results about "Positive patient" patented technology

Techniques are provided for controlling spinal cord stimulation (SCS) or other forms of neurostimulation. In one example, SCS treatment is delivered to a patient and nerve impulse firing signals are sensed along the spinal cord following the SCS treatment. The nerve impulse signals are analyzed to determine whether the signals are associated with effective SCS and then the delivery of additional SCS is controlled to improve SCS efficacy. For example, the nerve impulse signals can be analyzed to determine whether the signals are consistent with a positive patient mood associated with pain mitigation and, if not, SCS control parameters are adjusted to improve the efficacy of the SCS in reducing pain. In other examples, heart rate variability (HRV) is also used to control SCS. Still further, adjustments may be made to SCS control parameters to improve antiarrhythmic or sympatholytic effects associated with SCS. Techniques employing baseline / target calibration procedures are also described.

It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.

The present invention provides assay methods for the determination of one or more anti-drug antibody (ADA) isotypes in a sample. As a non-limiting example, the assays of the present invention are particularly useful for determining different ADA isotypes in samples from ADA-positive patients receiving an anti-TNFa drug such as REMICADETM (infliximab) or HUMIRATM (adalimumab). The present invention also provides methods for optimizing therapy and / or reducing toxicity in subjects receiving TNFa inhibitors for the treatment of TNFa-mediated disease or disorders.

A medicament for treating HPV infection and an application of the medicament in the preparation of medicaments for treating HPV infection. The invention is characterized in that the active component of the medicament is rabies vaccine for human, and a pharmaceutically-acceptable carrier is added to prepare the medicament; the invention also provides an application of the medicament in the preparation of medicaments for treating HPV infection, that is, a new application of rabies vaccine for human in the preparation of medicaments for treating human papillomavirus infection. The medicament (rabies vaccine for human) for treating human papillomavirus infection provided by the invention has obvious treatment effect on human papillomavirus infection; through animal experiments and preclinical observation, the medicament has satisfied and beneficial effect, has the characteristics of safety, effectiveness, and difficult recurrence after cure, and has a treatment negative conversion rate of up to 90% for human papillomavirus infection positive patients.

We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

The invention relates to oral powder with strict compatibility for treating hepatitis B. The oral powder has exact curative effect of treating hepatitis B virus carriers or hepatitis patients, improves the immunity of the hepatitis patients, is quick in enzyme reduction, and is used for repairing damaged liver cells; after the oral powder is taken by thousands of cases of patients, virus variation is not discovered in any case; and compared with similar medicaments, the negative conversion rate of big and small 3 positive patients is relatively improved and can reach about 60 percent.

The invention discloses a fusion antigen of the first hypervariable region of hepatitis C virus. The amino acid sequence of the fusion antigen is shown in SEQ ID No.1. The invention also discloses the detection of the fusion antigen in the preparation of hepatitis C virus HVR1 antibody. application in the kit. It is verified by experiments that the cross-reactivity of the fusion antigen of the present invention is significantly improved compared with the single fragment HVR1 antigen, and the detection coincidence rate with hepatitis C virus RNA-positive patients is as high as 99%. Since HVR1 is the main neutralizing epitope in hepatitis C virus, through the application of the antigen of the present invention, for the detection of hepatitis C virus HVR1 antibody, the purpose of comprehensive detection of HCV infection can be realized, and it can be used for the transformation of HCV disease. Problems such as reconciliation prognosis and interferon curative effect prediction can be effectively solved, and have great clinical application prospects.

Peptide sequences constituting T-cell epitopes of minor Histocompatibility antigen, HA-1. HA-1 is associated with Graft versus Host Disease. The peptides and their derivatives find many uses, for instance, in bone marrow transplantation, organ transplantation and in treatment of leukemia and non-hematopoietic tumors. The peptide and / or its derivatives can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. HA-1 is expressed by non-hematopoietic tumor cells. While absent in normal epithelial cells, tumor cells and tumor cell lines, particularly from epithelial origin, express HA-1 and are recognized by HA-1 cytotoxic T-cells. The invention provides means and methods for HA-1 specific immunotherapy for HA-1-positive patients with non-hematopoietic tumor cells.